Context Therapeutics reports Q2 EPS (9c), consensus (5c)

“We remain focused on progressing our clinical pipeline – CTIM-76, a selective Claudin 6 x CD3 bispecific antibody, and CT-95, an avidity enhanced mesothelin x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We expect to share initial dose escalation data for the CTIM-76 trial in the second quarter of 2026 and for the CT-95 trial by mid-2026.”